Joshua Bilsborrow MD MHS
Assistant Professor of Medicine (Rheumatology) at Yale University School of Medicine and the VA Connecticut Healthcare System
Join to View Full Profile
750 Campbell AvenueWest Haven, CT 06516
Phone+1 203-932-5711
Dr. Bilsborrow is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Joshua Bilsborrow is a rheumatologist based in West Haven, Connecticut. He completed his residency training in Internal Medicine and fellowship in Rheumatology at Yale-New Haven Medical Center. Dr. Bilsborrow graduated from the Vanderbilt University School of Medicine in 2013 and is currently employed as a rheumatologist at the Veterans Affairs Connecticut Healthcare System. He has numerous publications to his credit in respected journals such as Arthritis & Rheumatology, the American Journal of Medicine, Expert Opinion on Therapeutic Targets, and Aging Cell.
Education & Training
Yale-New Haven Medical CenterFellowship, Rheumatology, 2016 - 2020- Yale-New Haven Medical CenterResidency, Internal Medicine, 2013 - 2016
Vanderbilt University School of MedicineClass of 2013
Certifications & Licensure
CT State Medical License 2016 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Rheumatology
Publications & Presentations
PubMed
- 10 citationsGlobal Rheumatology Research: Frontiers, Challenges, and Opportunities.Joshua B. Bilsborrow, Ingris Peláez-Ballestas, Bernardo A. Pons-Estel, Christiaan Scott, Xinping Tian
Arthritis & Rheumatology. 2021-09-17 - 54 citationsChronic Chikungunya Arthritis and Rheumatoid Arthritis: What They Have in Common.J. Kennedy Amaral, Joshua B. Bilsborrow, Robert T. Schoen
The American Journal of Medicine. 2020-03-01 - 87 citationsMacrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.Joshua B. Bilsborrow, Edward Doherty, Pathricia V. Tilstam, Richard Bucala
Expert Opinion on Therapeutic Targets. 2019-08-20
Authored Content
- Clinical Features and Management of Chronic Chikungunya ArthritisJune 2019
Press Mentions
Yale Team Creates Rheumatology Curriculum in RwandaMay 2nd, 2023- Distinguished New Haven Rheumatologist Hutchinson RetiresFebruary 23rd, 2021
FibromyalgiaMarch 28th, 2020- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
